Understanding your potential buyer's journey step by step helps the marketing and sales teams to be very intentional about strategy. Photo via Getty Images

Creating a successful go-to-market strategy involves several crucial steps that help define a company’s target market and potential buyers, as well as the differentiators, the competitors and the value that a product or service brings to the market.

CEOs of middle market companies know what a GTM strategy is although they may not often use the terminology. It is the sales and marketing strategy and how the company will acquire new customers, and thus grow revenue for the business.

Understanding the buyer's journey is crucial. In a nutshell, this refers to the different stages a potential customer goes through before finally making a purchase. First, there's the awareness stage, where the customer realizes their need, and starts researching possible solutions.

Next is the consideration stage, where customers weigh the pros and cons of various companies, comparing features, benefits, and pricing. Finally, in the decision stage, the customer decides on a specific solution based on the input they gathered along the way. By understanding and effectively utilizing this framework, marketing and sales teams can customize their strategy to promote trust, establish credibility, and meet revenue goals.

Understanding the journey step by step helps the marketing and sales teams to be very intentional about strategy.

Identifying an ideal customer profile (ICP)

A good way to approach this is by looking at the existing customer base for any common traits by conducting revenue analysis. Likely, there will be trends in the customer data that can be very informative on ways to target new customers. Look at data points such as duration as a customer, growth in revenue per customer, industry, region, etc. to define customer personas that may be ideal for the business.

Once the targets are determined, think about ways these potential buyers get their industry or professional information. Who do they follow? What do they care about?

Examining market trends and doing competitor research will lead to the creation of customer personas that may be outside of the current customer base.

Doing market research is critical to understanding the size of the market, so companies can determine their market share. Once a team really knows the target audience, it can create more effective content and digital marketing strategies that resonate with a company’s ideal customers and ultimately lead to higher conversion rates and revenue growth.

Catering to the buyer's journey

The potential buyer is going to need different things from marketing and sales at every stage of the journey. During the awareness stage, potential buyers are just starting to recognize that they have a problem, or a need. They aren’t ready to buy but they want information to better understand their situation. Show them content that addresses their pain points and provides a solution. Blog posts, e-books, whitepapers, and webinars are all ways to do this.

Once a buyer understands their problem better, they will actively search online for solutions. There is a lot of comparison going on now. Buyers in today’s market expect more transparency from B2B companies than in the past. To capitalize on this stage, a company needs to have detailed product information and case studies that demonstrate the value of a service or solution. Some companies will produce comparison guides to show their differentiators from the competition.

At the end of the journey, a buyer has narrowed down their options and is ready to make a purchase. They may need a little more information, or reassurance that their decision is the right one. Customer testimonials and reviews as well as interaction with the sales team will help to move a customer over the finish time.

Tailored messaging for different decision-makers

In complex B2B sales, there are usually multiple decision-makers involved, with stakeholders from various departments weighing in on the decision. Therefore, it is vital to have a different message tailored to each decision-maker, built into the overall messaging.

There is never going to be just one decision maker, especially if it’s a high dollar product or service. Finance is going to weigh in. The user is going to want a say. Communication to stakeholders across multiple departments in the company is key.

Prioritizing highly converting marketing tactics

An underappreciated element of any Go To Market strategy is prioritizing marketing and sales tactics. With limited resources and budget, identifying the most highly converting tactics is essential. And as with everything else, it also requires a deep understanding of the buyer.

For example, a company may prioritize trade shows as their most highly converting tactic because decision-makers and buyers in their niche market attend these events. Some companies may benefit more from paid advertising, while others may prioritize content creation or email campaigns. Tactics will be dependent on industry, target audience, and goals.

Companies should focus on tactics that are most likely to generate the highest ROI.

Both the marketing and sales teams need to understand the buyer's journey and focus on their needs and pain points at each step. This means adopting a customer-centric approach. By doing so, businesses can create a cohesive revenue team that works together to identify the most effective tactics and improve revenue growth.

At Craig Group, we have seen first hand that companies who implement a comprehensive go-to-market strategy, track their progress and adjust their approach as necessary, have a higher chance of meeting their revenue targets.

This approach is very effective if the necessary effort and resources are dedicated to the process. The strategic guidance and support of the right team can help develop and refine a GTM approach that is tailored to the company and aligned with its goals.

------

Libby Covington is partner at Houston-based The Craig Group, a strategic digital marketing solutions consulting firm. Her specialty is in understanding how sales and marketing work together effectively.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Modular nuclear reactor co. NuScale Power moves into Houston market

New to Hou

The nuclear energy renaissance continues in Texas with an announcement by NuScale Power. The Oregon-based provider of proprietary and innovative advanced small modular reactor (SMR) nuclear technology announced in April it would be opening office space in Houston’s CityCentre.

“Opening this space in Houston underscores our commitment to meeting rising energy demand with safe, scalable nuclear technology,” John Hopkins, NuScale president and CEO, said in a news release. “This move expands our presence in a key market for partners, prospective customers, and stakeholders in addition to positioning us for the future as we focus on the near-term deployment of our industry-leading technology. Texas is leading the way in embracing advanced nuclear for grid resilience and industrial decarbonization, and we’re proud to expand our footprint and capabilities in this important region.”

Interest in nuclear power has been growing in recent years thanks to tensions with oil-rich nations, concerns about man-made climate change from fossil fuels, and the rapidly increasing power needs of data centers. Both Dow and Texas A&M University have announced expanded nuclear power projects in the last year, with an eye of changing the face of Texas’s energy industry through smaller, safer fission reactors.

Enter NuScale, founded in 2007 from technology developed at the University of Oregon. Their modular SMR technology generates 77 megawatts and is one of the only small modular reactors (SMR) to receive design approval from the U.S. Nuclear Regulatory Commission (NRC). These advances have led to runaway success for NuScale, whose stock has risen by more than 1,670 percent since the start of 2024.

The new operations campus in CityCentre is expected to facilitate the movement, installation and coordination of NuScale technology into the various energy systems. Typically, SMRs are used for off-grid installations, desalination operations, mining facilities and similar areas that lack infrastructure. However, the modularity means that they can be easily deployed to a variety of areas.

It comes none too soon. ERCOT projects that Texas data centers alone will require 77,965 megawatts by 2030.

---

This article first appeared on EnergyCapitalHTX.com.

Pharma giant considers Houston for $1 billion manufacturing campus

in the works

Another pharmaceutical giant is considering Houston’s Generation Park for a manufacturing hub.

According to a recent filing with the Texas Jobs, Energy, Technology and Innovation (JETI) program, Bristol Myers Squibb Co. is considering the northeast Houston management district for a new $1 billion multi-modal pharmaceutical manufacturing campus.

If approved, the campus, known as Project Argonaut, could create 489 jobs in Texas by 2031. Jobs would include operations technicians, engineering roles, administrative and management roles, production specialists, maintenance support, and quality control/assurance. The company predicts annual average wages for these positions to be around $96,000, according to the filing.

The project currently includes the 600,000-square-foot facility, but according to the filing, Bristol Myers Squibb “envisions this site growing in scale and capability well beyond its opening configuration."

The Texas JETI program offers companies temporary school property tax limitations in exchange for major capital investment and job creation. E.R. Squibb & Sons LLC applied for a 10-year tax abatement agreement in the Sheldon Independent School District.

The agreement promises a $ 1 billion investment. Construction would begin in 2027 and wrap in 2029.

“The proposed project reflects [Bristol Myers Squibb Co.’s] enduring commitment to bringing innovative medicines to patients and ensuring the long-term supply reliability they depend on,” the filing says. “The proposed project is purpose-built to support and manufacture medicines spanning multiple therapeutic areas and modalities, positioning the site as a long-term launch and commercial campus for decades to come. These medicines will provide therapies to the [Bristol Myers Squibb Co.’s] patients located in markets both nationally and internationally.”

The Fortune 100 company is considering 16 other cities for the new manufacturing facility in the Central and Eastern markets in the U.S. According to the Houston Chronicle, Bristol Myers Squibb Co is still in the “evaluation process” for its potential manufacturing site.

Last fall, Eli Lilly and Co. selected Generation Park for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

Houston health tech co. lands NIH grant for AI cancer prediction tool

fresh funding

Houston-based CellChorus and Stanford Medicine were recently awarded a Phase I Small Business Innovation Research grant for the company's AI platform to test how certain cancer patients will respond to therapies.

The funding comes from the National Cancer Institute of the National Institutes of Health. According to a filing, the grant totaled just under $400,000.

CellChorus, which spun out from the University of Houston’s Technology Bridge, has developed TIMING (Time-lapse Imaging Microscopy In Nanowell Grids), which analyzes the behavior of thousands of individual immune cells over time and can identify early indicators of treatment success or failure.

The company will work with Stanford's Dr. David Miklos and Dr. Saurabh Dahiya, who have built the Bone Marrow Transplantation and Cell Therapy Biobank. The biobank manages and stores biological samples from patients treated at their clinic and in clinical trials.

"Predicting which patients will achieve durable responses after CAR-T therapy remains one of the most important challenges in the field,” Miklos said in a news release. “We aim to uncover functional cellular signatures that can guide treatment decisions and improve patient outcomes.”

The project will specifically profile cells from patients with relapsed/refractory large B-cell lymphoma (r/rLBCL). According to CellChorus, only about half of r/rLBCL patients who receive CAR-T therapy "achieve a durable, long-term remission." Others do not respond to therapy or experience relapse.

“The sooner we know whether a cancer therapy is working, the better. To maximize patient benefit, we need technology that can provide a robust and early prediction of response to therapy. The technology needs to be scalable, cost-efficient, and capable of rapid turnaround times,” Rebecca Berdeaux, chief scientific officer of CellChorus, added in the release. “We are excited to work with Drs. David Miklos and Saurabh Dahiya and their colleagues on this very important project.”

CellChorus has previously received SBIR grants from federal agencies, including a $2.5 million award in 2024 from its National Center for Advancing Translational Sciences (NCATS) and a $2.3 million SBIR Fast-Track award from the National Institute of General Medical Sciences in 2023.